INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34401, 12938, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34402, 12940, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34403, 13330, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34404, 13346, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34405, 13455, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34406, 13457, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34407, 15444, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34408, 16999, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34409, 27726, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34410, 29411, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34411, 29412, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34412, 29413, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34413, 29414, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34414, 30031, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34415, 30034, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34416, 30036, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34417, 31696, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34418, 55, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34419, 71, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34420, 131, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34421, 133, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34422, 135, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34423, 137, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34424, 3222, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34425, 3223, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34426, 7574, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34427, 9055, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34428, 12351, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34429, 12352, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34430, 12934, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34431, 12935, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34432, 12936, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34433, 12938, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34434, 12940, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34435, 13330, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34436, 13346, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34437, 13455, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34438, 13457, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34439, 15444, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34440, 16999, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34441, 27726, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34442, 29411, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34443, 29412, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34444, 29413, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34445, 29414, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34446, 30031, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34447, 30034, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34448, 30036, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34449, 31696, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34450, 0, 'Busulfan', 'Infections', 'Busulfan can induce severe and prolonged myelosuppression.  Treatment with busulfan should not be initiated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with busulfan.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34451, 0, 'Busulfan', 'Bone Marrow Failure Disorders', 'Busulfan induces severe and prolonged myelosuppression at the recommended dosage.  Hematopoietic progenitor cell transplantation is required to prevent potentially fatal complications of the prolonged myelosuppression.  It is recommended to closely monitor complete blood counts, including white blood cell differentials, and quantitative platelet counts daily during treatment and until engraftment is demonstrated.  Extreme caution should be exercised if busulfan is administered in patients whose bone marrow reserve may be compromised by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression, such as fever, sore throat, local infection, bleeding, or symptoms of anemia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34452, 0, 'Busulfan', 'Cardiac Tamponade', 'Cardiac tamponade during high dose busulfan therapy combined with cyclophosphamide has been reported in pediatric patients with thalassemia.  Abdominal pain and vomiting may precede the tamponade.  Cardiac tamponade can result in death and therapy with busulfan should be administered cautiously to patients with thalassemia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34453, 0, 'Busulfan', 'Epilepsy', 'Seizures have been reported in patients receiving high doses of busulfan.  Therapy with busulfan should be administered cautiously to patients with a history of a seizure disorder or head trauma or who are receiving other potentially epileptogenic drugs.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34454, 1832, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34455, 1833, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34456, 3857, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34457, 3907, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34458, 4091, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34459, 5699, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34460, 7750, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34461, 15599, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34462, 17197, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34463, 20013, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34464, 20639, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34465, 21123, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34466, 23755, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34467, 25706, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34468, 25855, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34469, 30241, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34470, 30242, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34471, 31875, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34472, 1832, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34473, 1833, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34474, 3857, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34475, 3907, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34476, 4091, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34477, 5699, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34478, 7750, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34479, 15599, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34480, 17197, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34481, 20013, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34482, 20639, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34483, 21123, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34484, 23755, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34485, 25706, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34486, 25855, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34487, 30241, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34488, 30242, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34489, 31875, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34490, 1832, 'Cabergoline', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34491, 1833, 'Cabergoline', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34492, 3857, 'Cabergoline', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34493, 3907, 'Cabergoline', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34494, 4091, 'Cabergoline', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34495, 5699, 'Cabergoline', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34496, 7750, 'Cabergoline', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34497, 15599, 'Cabergoline', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34498, 17197, 'Cabergoline', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34499, 20013, 'Cabergoline', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34500, 20639, 'Cabergoline', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
